137,622 Shares in 23andMe Holding Co. (NASDAQ:ME) Acquired by BKA Wealth Consulting Inc.

BKA Wealth Consulting Inc. purchased a new position in shares of 23andMe Holding Co. (NASDAQ:ME) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 137,622 shares of the company’s stock, valued at approximately $126,000.

Other hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. grew its position in 23andMe by 3.1% during the third quarter. Vanguard Group Inc. now owns 28,145,216 shares of the company’s stock valued at $27,518,000 after buying an additional 834,504 shares during the period. Wittenberg Investment Management Inc. lifted its holdings in 23andMe by 88.8% in the third quarter. Wittenberg Investment Management Inc. now owns 1,144,484 shares of the company’s stock worth $1,119,000 after purchasing an additional 538,230 shares during the period. Swiss National Bank increased its holdings in shares of 23andMe by 2.5% in the 3rd quarter. Swiss National Bank now owns 579,800 shares of the company’s stock valued at $567,000 after purchasing an additional 14,000 shares during the period. Commonwealth Equity Services LLC boosted its position in shares of 23andMe by 4.6% in the third quarter. Commonwealth Equity Services LLC now owns 370,934 shares of the company’s stock valued at $363,000 after acquiring an additional 16,390 shares during the period. Finally, Mirador Capital Partners LP bought a new position in 23andMe in the fourth quarter valued at about $280,000. 36.10% of the stock is owned by institutional investors.

23andMe Stock Down 0.0 %

23andMe stock traded down $0.00 during mid-day trading on Thursday, reaching $0.47. 539,939 shares of the company’s stock were exchanged, compared to its average volume of 7,199,167. 23andMe Holding Co. has a twelve month low of $0.35 and a twelve month high of $2.21. The company has a market cap of $225.52 million, a P/E ratio of -0.42 and a beta of 1.27. The company has a fifty day moving average of $0.52 and a 200-day moving average of $0.72.

23andMe (NASDAQ:ME) last issued its quarterly earnings data on Wednesday, February 7th. The company reported ($0.17) earnings per share for the quarter. The firm had revenue of $44.75 million during the quarter, compared to the consensus estimate of $56.30 million. 23andMe had a negative net margin of 210.48% and a negative return on equity of 52.99%.

Wall Street Analyst Weigh In

Separately, Citigroup lowered their target price on 23andMe from $0.85 to $0.47 and set a “neutral” rating for the company in a report on Tuesday, April 16th.

23andMe Profile

23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.